Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.

Payton M, Cheung HK, Ninniri MSS, Marinaccio C, Wayne WC, Hanestad K, Crispino JD, Juan G, Coxon A.

Mol Cancer Ther. 2018 Dec;17(12):2575-2585. doi: 10.1158/1535-7163.MCT-18-0186. Epub 2018 Sep 28.

PMID:
30266802
2.

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, Whittington DA, Huang X, Poppe L, Cheng AC, Cardozo M, Houze J, Li Y, Lucas B, Paras NA, Wang X, Taygerly JP, Vimolratana M, Zancanella M, Zhu L, Cajulis E, Osgood T, Sun J, Damon L, Egan RK, Greninger P, McClanaghan JD, Gong J, Moujalled D, Pomilio G, Beltran P, Benes CH, Roberts AW, Huang DC, Wei A, Canon J, Coxon A, Hughes PE.

Cancer Discov. 2018 Dec;8(12):1582-1597. doi: 10.1158/2159-8290.CD-18-0387. Epub 2018 Sep 25.

PMID:
30254093
3.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN.

Cancer Discov. 2018 Dec;8(12):1598-1613. doi: 10.1158/2159-8290.CD-18-0277. Epub 2018 Sep 25.

PMID:
30254092
4.

Prognostic Significance of Post-Operative Morbidity Severity Score After Potentially Curative D2 Gastrectomy for Carcinoma.

Powell A, Coxon AH, Patel N, Chan D, Christian A, Lewis W.

J Gastrointest Surg. 2018 May 15. doi: 10.1007/s11605-018-3787-9. [Epub ahead of print]

5.

Does Duration of Pain at Baseline Influence Clinical Outcomes of Low Back Pain Patients Managed on an Evidence-based Pathway?

Jess MA, Ryan C, Hamilton S, Wellburn S, Atkinson G, Greenough C, Coxon A, Ferguson D, Fatoye F, Dickson J, Jones A, Martin D.

Spine (Phila Pa 1976). 2018 Sep 1;43(17):E998-E1004. doi: 10.1097/BRS.0000000000002612.

PMID:
29470277
6.

Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy.

Zheng H, Bae Y, Kasimir-Bauer S, Tang R, Chen J, Ren G, Yuan M, Esposito M, Li W, Wei Y, Shen M, Zhang L, Tupitsyn N, Pantel K, King C, Sun J, Moriguchi J, Jun HT, Coxon A, Lee B, Kang Y.

Cancer Cell. 2017 Dec 11;32(6):731-747.e6. doi: 10.1016/j.ccell.2017.11.002.

PMID:
29232552
7.

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.

Ross SL, Sherman M, McElroy PL, Lofgren JA, Moody G, Baeuerle PA, Coxon A, Arvedson T.

PLoS One. 2017 Aug 24;12(8):e0183390. doi: 10.1371/journal.pone.0183390. eCollection 2017.

8.

Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity.

van den Heuvel CNAM, Navis AC, de Bitter T, Amiri H, Verrijp K, Heerschap A, Rex K, Dussault I, Caenepeel S, Coxon A, Span PN, Wesseling P, Hendriks W, Leenders WPJ.

Mol Cancer Res. 2017 Nov;15(11):1587-1597. doi: 10.1158/1541-7786.MCR-17-0177. Epub 2017 Jul 27.

9.

Implementing enhanced recovery pathways: a literature review with realist synthesis.

Coxon A, Nielsen K, Cross J, Fox C.

Hosp Pract (1995). 2017 Oct;45(4):165-174. doi: 10.1080/21548331.2017.1351858. Epub 2017 Jul 12. Review. Erratum in: Hosp Pract (1995). 2018 Aug;46(3):163.

10.

Response-Derived Input Function Estimation for Dynamic Contrast-Enhanced MRI Demonstrated by Anti-DLL4 Treatment in a Murine U87 Xenograft Model.

Silva MD, Yerby B, Moriguchi J, Gomez A, Toni Jun H, Coxon A, Ungersma SE.

Mol Imaging Biol. 2017 Oct;19(5):673-682. doi: 10.1007/s11307-017-1065-y.

PMID:
28265853
11.

MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.

Caenepeel S, Cooke K, Wadsworth S, Huang G, Robert L, Moreno BH, Parisi G, Cajulis E, Kendall R, Beltran P, Ribas A, Coxon A, Hughes PE.

Oncotarget. 2017 Mar 14;8(11):17795-17809. doi: 10.18632/oncotarget.14855.

12.

Hedgehog Signaling Inhibitors Fail to Reduce Merkel Cell Carcinoma Viability.

Carroll TM, Williams JS, Daily K, Rogers T, Gelb T, Coxon A, Wang SQ, Crago AM, Busam KJ, Brownell I.

J Invest Dermatol. 2017 May;137(5):1187-1190. doi: 10.1016/j.jid.2017.01.008. Epub 2017 Jan 25. No abstract available.

13.

Attitudes and barriers to providing dietary advice: perceptions of dental hygienists and oral health therapists.

Hayes MJ, Wallace JP, Coxon A.

Int J Dent Hyg. 2016 Nov;14(4):255-260. doi: 10.1111/idh.12239. Epub 2016 Jul 26.

PMID:
27457776
14.

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.

Hughes PE, Rex K, Caenepeel S, Yang Y, Zhang Y, Broome MA, Kha HT, Burgess TL, Amore B, Kaplan-Lefko PJ, Moriguchi J, Werner J, Damore MA, Baker D, Choquette DM, Harmange JC, Radinsky R, Kendall R, Dussault I, Coxon A.

Mol Cancer Ther. 2016 Jul;15(7):1568-79. doi: 10.1158/1535-7163.MCT-15-0871. Epub 2016 Apr 19.

15.

Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma.

Du Z, Caenepeel S, Shen Y, Rex K, Zhang Y, He Y, Tang ET, Wang O, Zhong W, Zhou H, Huang J, Huang E, Hu L, Coxon A, Zhang M.

Mol Cancer Ther. 2016 Jun;15(6):1227-37. doi: 10.1158/1535-7163.MCT-15-0745. Epub 2016 Mar 29.

16.

'You're never making just one decision': exploring the lived experiences of ambulance Emergency Operations Centre personnel.

Coxon A, Cropley M, Schofield P, Start K, Horsfield C, Quinn T.

Emerg Med J. 2016 Sep;33(9):645-51. doi: 10.1136/emermed-2015-204841. Epub 2016 Mar 21.

PMID:
27002162
17.

Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.

Boezio AA, Copeland KW, Rex K, K Albrecht B, Bauer D, Bellon SF, Boezio C, Broome MA, Choquette D, Coxon A, Dussault I, Hirai S, Lewis R, Lin MH, Lohman J, Liu J, Peterson EA, Potashman M, Shimanovich R, Teffera Y, Whittington DA, Vaida KR, Harmange JC.

J Med Chem. 2016 Mar 24;59(6):2328-42. doi: 10.1021/acs.jmedchem.5b01716. Epub 2016 Feb 11.

PMID:
26812066
18.

Polyomavirus T antigens activate an antiviral state.

Giacobbi NS, Gupta T, Coxon AT, Pipas JM.

Virology. 2015 Feb;476:377-385. doi: 10.1016/j.virol.2014.12.032. Epub 2015 Jan 10.

19.

The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.

Canon J, Osgood T, Olson SH, Saiki AY, Robertson R, Yu D, Eksterowicz J, Ye Q, Jin L, Chen A, Zhou J, Cordover D, Kaufman S, Kendall R, Oliner JD, Coxon A, Radinsky R.

Mol Cancer Ther. 2015 Mar;14(3):649-58. doi: 10.1158/1535-7163.MCT-14-0710. Epub 2015 Jan 7.

20.

Assessment of cancer cell line representativeness using microarrays for Merkel cell carcinoma.

Daily K, Coxon A, Williams JS, Lee CR, Coit DG, Busam KJ, Brownell I.

J Invest Dermatol. 2015 Apr;135(4):1138-1146. doi: 10.1038/jid.2014.518. Epub 2014 Dec 18.

21.

Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method.

Payton M, Jun T, Wayne W, Yu D, Manoukian R, Chung G, Zhang N, Sun JR, Kaplan-Lefko P, Scully S, Van G, Radinsky R, Kendall R, Oliner J, Coxon A.

Lab Invest. 2014 Nov;94(11):1296-308. doi: 10.1038/labinvest.2014.116. Epub 2014 Sep 22.

22.

The role of angiopoietins as potential therapeutic targets in renal cell carcinoma.

Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, Alsop DC, Mier JW, Atkins MB, Coxon A, Oliner J, Bhatt RS.

Transl Oncol. 2014 Apr;7(2):188-95. doi: 10.1016/j.tranon.2014.02.003. Epub 2014 Mar 4.

23.

Sphingosine kinase activity is not required for tumor cell viability.

Rex K, Jeffries S, Brown ML, Carlson T, Coxon A, Fajardo F, Frank B, Gustin D, Kamb A, Kassner PD, Li S, Li Y, Morgenstern K, Plant M, Quon K, Ruefli-Brasse A, Schmidt J, Swearingen E, Walker N, Wang Z, Watson JE, Wickramasinghe D, Wong M, Xu G, Wesche H.

PLoS One. 2013 Jul 5;8(7):e68328. doi: 10.1371/journal.pone.0068328. Print 2013.

24.

Structure guided design of a series of sphingosine kinase (SphK) inhibitors.

Gustin DJ, Li Y, Brown ML, Min X, Schmitt MJ, Wanska M, Wang X, Connors R, Johnstone S, Cardozo M, Cheng AC, Jeffries S, Franks B, Li S, Shen S, Wong M, Wesche H, Xu G, Carlson TJ, Plant M, Morgenstern K, Rex K, Schmitt J, Coxon A, Walker N, Kayser F, Wang Z.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4608-16. doi: 10.1016/j.bmcl.2013.06.030. Epub 2013 Jun 20.

PMID:
23845219
25.

Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.

Rex K, Lewis XZ, Gobalakrishnan S, Glaus C, Silva MD, Radinsky R, Burgess TL, Gambhir SS, Coxon A.

Nucl Med Biol. 2013 May;40(4):458-63. doi: 10.1016/j.nucmedbio.2013.01.004. Epub 2013 Feb 28.

PMID:
23454250
26.

Do L5 and s1 nerve root compressions produce radicular pain in a dermatomal pattern?

Taylor CS, Coxon AJ, Watson PC, Greenough CG.

Spine (Phila Pa 1976). 2013 May 20;38(12):995-8. doi: 10.1097/BRS.0b013e318286b7dd.

PMID:
23324941
27.

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.

Coxon A, Ziegler B, Kaufman S, Xu M, Wang H, Weishuhn D, Schmidt J, Sweet H, Starnes C, Saffran D, Polverino A.

Mol Cancer. 2012 Sep 19;11:70. doi: 10.1186/1476-4598-11-70.

28.

AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases.

Oliner JD, Bready J, Nguyen L, Estrada J, Hurh E, Ma H, Pretorius J, Fanslow W, Nork TM, Leedle RA, Kaufman S, Coxon A.

Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2170-80. doi: 10.1167/iovs.11-7381.

PMID:
22410553
29.

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J, Wang L, Radinsky R, Kendall R, Hughes P, Polverino A.

J Endocrinol Invest. 2012 Feb;35(2):181-90. doi: 10.3275/7609. Epub 2011 Mar 21.

PMID:
21422803
30.

Molecular imaging of c-Met tyrosine kinase activity.

Zhang L, Virani S, Zhang Y, Bhojani MS, Burgess TL, Coxon A, Galban CJ, Ross BD, Rehemtulla A.

Anal Biochem. 2011 May 1;412(1):1-8. doi: 10.1016/j.ab.2011.01.028. Epub 2011 Jan 27.

31.

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.

Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun JR, Estrada J, Bolon B, McCabe J, Wang L, Rex K, Caenepeel S, Hughes P, Cordover D, Kim H, Han SJ, Michaels ML, Hsu E, Shimamoto G, Cattley R, Hurh E, Nguyen L, Wang SX, Ndifor A, Hayward IJ, Falcón BL, McDonald DM, Li L, Boone T, Kendall R, Radinsky R, Oliner JD.

Mol Cancer Ther. 2010 Oct;9(10):2641-51. doi: 10.1158/1535-7163.MCT-10-0213.

32.

Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.

Kruser TJ, Wheeler DL, Armstrong EA, Iida M, Kozak KR, van der Kogel AJ, Bussink J, Coxon A, Polverino A, Harari PM.

Clin Cancer Res. 2010 Jul 15;16(14):3639-47. doi: 10.1158/1078-0432.CCR-09-3385. Epub 2010 May 27.

33.

Isotope fractionation during precipitation of methamphetamine HCl and discrimination of seized forensic samples.

David GE, Coxon A, Frew RD, Hayman AR.

Forensic Sci Int. 2010 Jul 15;200(1-3):123-9. doi: 10.1016/j.forsciint.2010.03.043. Epub 2010 Apr 28.

PMID:
20430545
34.

Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis.

Canon J, Bryant R, Roudier M, Osgood T, Jones J, Miller R, Coxon A, Radinsky R, Dougall WC.

Bone. 2010 Jun;46(6):1613-9. doi: 10.1016/j.bone.2010.03.001. Epub 2010 Mar 6.

PMID:
20215062
35.

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.

Hashizume H, Falcón BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM.

Cancer Res. 2010 Mar 15;70(6):2213-23. doi: 10.1158/0008-5472.CAN-09-1977. Epub 2010 Mar 2.

36.

Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types.

Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J, Coxon A, Huard JN, Xu R, Peach ML, Juan G, Kaufman S, Chen Q, Bianchi A, Kordich JJ, Ma M, Foltz IN, Gliniak BC.

Cancer Biol Ther. 2010 Apr 15;9(8):618-31. Epub 2010 Apr 20.

PMID:
20150762
37.

Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells.

Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, Busse L, Swift S, Elliott S, Begley CG.

Blood. 2010 May 27;115(21):4264-72. doi: 10.1182/blood-2009-10-248666. Epub 2010 Feb 2.

38.

Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.

Burgess TL, Sun J, Meyer S, Tsuruda TS, Sun J, Elliott G, Chen Q, Haniu M, Barron WF, Juan T, Zhang K, Coxon A, Kendall RL.

Mol Cancer Ther. 2010 Feb;9(2):400-9. doi: 10.1158/1535-7163.MCT-09-0824. Epub 2010 Feb 2.

39.

Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.

Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE.

Cancer Res. 2010 Jan 15;70(2):639-45. doi: 10.1158/0008-5472.CAN-09-1121. Epub 2010 Jan 12.

40.

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.

Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L.

Clin Cancer Res. 2010 Jan 15;16(2):699-710. doi: 10.1158/1078-0432.CCR-09-1365. Epub 2010 Jan 12.

41.

Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer.

Komiya T, Coxon A, Park Y, Chen WD, Zajac-Kaye M, Meltzer P, Karpova T, Kaye FJ.

Oncogene. 2010 Mar 18;29(11):1672-80. doi: 10.1038/onc.2009.453. Epub 2009 Dec 14.

PMID:
20010869
42.

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.

Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K, Osgood T, Coxon A, Burgess TL, Vande Woude GF.

Mol Cancer Ther. 2009 Oct;8(10):2803-10. doi: 10.1158/1535-7163.MCT-09-0125.

43.

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.

Falcón BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, Oliner JD, McDonald DM.

Am J Pathol. 2009 Nov;175(5):2159-70. doi: 10.2353/ajpath.2009.090391. Epub 2009 Oct 8.

44.

Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.

Coxon A, Rex K, Meyer S, Sun J, Sun J, Chen Q, Radinsky R, Kendall R, Burgess TL.

Mol Cancer Ther. 2009 May;8(5):1119-25. doi: 10.1158/1535-7163.MCT-08-1032. Epub 2009 May 12.

45.

Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.

Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A.

Clin Cancer Res. 2009 Jan 1;15(1):110-8. doi: 10.1158/1078-0432.CCR-08-1155.

46.

Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase.

Cee VJ, Cheng AC, Romero K, Bellon S, Mohr C, Whittington DA, Bak A, Bready J, Caenepeel S, Coxon A, Deak HL, Fretland J, Gu Y, Hodous BL, Huang X, Kim JL, Lin J, Long AM, Nguyen H, Olivieri PR, Patel VF, Wang L, Zhou Y, Hughes P, Geuns-Meyer S.

Bioorg Med Chem Lett. 2009 Jan 15;19(2):424-7. doi: 10.1016/j.bmcl.2008.11.056. Epub 2008 Nov 20.

PMID:
19062275
47.

Design, synthesis, and biological evaluation of potent c-Met inhibitors.

D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS.

J Med Chem. 2008 Sep 25;51(18):5766-79. doi: 10.1021/jm8006189.

PMID:
18763753
48.

Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.

Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL, Dussault I.

Cancer Res. 2008 Aug 15;68(16):6680-7. doi: 10.1158/0008-5472.CAN-07-6782.

49.

Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.

Bauer D, Whittington DA, Coxon A, Bready J, Harriman SP, Patel VF, Polverino A, Harmange JC.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4844-8. doi: 10.1016/j.bmcl.2008.07.080. Epub 2008 Jul 24.

PMID:
18682324
50.

Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras.

Park Y, Kubo A, Komiya T, Coxon A, Beebe K, Neckers L, Meltzer PS, Kaye FJ.

Cell Cycle. 2008 Aug;7(15):2384-91. Epub 2008 May 30.

Supplemental Content

Support Center